AVTX Reports Q1 2026 Net Loss $19.6M, Diluted EPS -$1.25, $431.3M Financing
Avalo Therapeutics, Inc. Common Stock · PHARMACEUTICAL PREPARATIONS · Now $15.75
-19% in 3d after detection
Post-detection moves
1h
—
1d
-4.2%
3d
-19%
7d
-18%
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS